Cancer mutation could be used to target CRISPR therapy
Researchers reveal protospacer adjacent motif mutations (PAM sites) on the NRF2 gene of cancers could be used to guide CRISPR gene editing.
List view / Grid view
Researchers reveal protospacer adjacent motif mutations (PAM sites) on the NRF2 gene of cancers could be used to guide CRISPR gene editing.
Research into gynaecological cancers has shown that removing the ETV4 protein from endometrial cancer cells reduces oestrogen signalling and subsequently tumour growth.
New research has categorised hundreds of cancers based on their common protein mutations, highlighting cell components and tumour microenvironments as possible new therapy targets.